FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111444324> ?p ?o ?g. }

• W3111444324 endingPage "e0243729" @default.
• W3111444324 startingPage "e0243729" @default.
• W3111444324 abstract "This study aimed to directly analyze the potential relationship of anti-nuclear antibodies (ANA) before and after the administration of TNF-α inhibitors (TNFi) with the appearance of anti-drug antibodies (ADrA) in patients with rheumatoid arthritis (RA). A total of 121 cases, viz., 38, 53, and 30 cases treated with infliximab (IFX), adalimumab (ADA), and etanercept (ETN), respectively, were enrolled. The ANA titers were measured using indirect immunefluorescence assay (IF-ANA) and multiplex flow immunoassay (ANA Screen) before and serially during the therapy. The anti-IFX antibodies (HACA) and anti-ADA antibodies (AAA) were measured with a radioimmunoassay. ADrA turned positive in 14 (36.8%) among 38 patients treated with IFX, and 16 (30.2%) among 53 treated with ADA. All of them were positive for IF-ANA before TNFi administration, while ADrA never appeared in any of the 15 patients negative for IF-ANA (< 40). IF-ANA of high titers (≥ 320 and ≥ 640) before IFX treatment showed a significant association with the appearance of HACA 52 weeks after IFX ( P = 0.040 and 0.017, respectively), whereas AAA appearance was not related to IF-ANA titers before treatment. Moreover, IF-ANA of high titers before IFX treatment was significantly associated with inefficacy and discontinuation of the treatment. The positivity of anti-SS-A antibodies before therapy might be a risk factor for ADrA appearance in patients treated with IFX or ADA. The percentage of patients whose IF-ANA titers increased was significantly higher with IFX than with ADA or ETN treatments ( P = 0.026 and 0.022, respectively). High ANA titers and positive ANA Screen after IFX therapy showed a significant association with HACA appearance and possibly led to treatment failure. Among the three TNFi, only IFX showed a close relationship with IF-ANA and ADrA appearance, suggesting the interaction of immunogenicity with autoimmunity as well as the advantage of ANA measurement before TNFi therapy." @default.
• W3111444324 created "2020-12-21" @default.
• W3111444324 creator A5000822704 @default.
• W3111444324 creator A5002698858 @default.
• W3111444324 creator A5012356502 @default.
• W3111444324 creator A5026908779 @default.
• W3111444324 creator A5032051871 @default.
• W3111444324 creator A5045852119 @default.
• W3111444324 creator A5083714778 @default.
• W3111444324 creator A5088844786 @default.
• W3111444324 date "2020-12-14" @default.
• W3111444324 modified "2023-10-11" @default.
• W3111444324 title "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
• W3111444324 cites W1518420099 @default.
• W3111444324 cites W1588728586 @default.
• W3111444324 cites W1955559925 @default.
• W3111444324 cites W2020927895 @default.
• W3111444324 cites W2029993898 @default.
• W3111444324 cites W2078905277 @default.
• W3111444324 cites W2127532898 @default.
• W3111444324 cites W2141395406 @default.
• W3111444324 cites W2147751728 @default.
• W3111444324 cites W2154144521 @default.
• W3111444324 cites W2164764408 @default.
• W3111444324 cites W2226466280 @default.
• W3111444324 cites W2257745151 @default.
• W3111444324 cites W2523653129 @default.
• W3111444324 cites W2608850138 @default.
• W3111444324 cites W2758711729 @default.
• W3111444324 cites W2913598940 @default.
• W3111444324 cites W4239125410 @default.
• W3111444324 doi "https://doi.org/10.1371/journal.pone.0243729" @default.
• W3111444324 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7735569" @default.
• W3111444324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33315881" @default.
• W3111444324 hasPublicationYear "2020" @default.
• W3111444324 type Work @default.
• W3111444324 sameAs 3111444324 @default.
• W3111444324 citedByCount "5" @default.
• W3111444324 countsByYear W31114443242022 @default.
• W3111444324 countsByYear W31114443242023 @default.
• W3111444324 crossrefType "journal-article" @default.
• W3111444324 hasAuthorship W3111444324A5000822704 @default.
• W3111444324 hasAuthorship W3111444324A5002698858 @default.
• W3111444324 hasAuthorship W3111444324A5012356502 @default.
• W3111444324 hasAuthorship W3111444324A5026908779 @default.
• W3111444324 hasAuthorship W3111444324A5032051871 @default.
• W3111444324 hasAuthorship W3111444324A5045852119 @default.
• W3111444324 hasAuthorship W3111444324A5083714778 @default.
• W3111444324 hasAuthorship W3111444324A5088844786 @default.
• W3111444324 hasBestOaLocation W31114443241 @default.
• W3111444324 hasConcept C126322002 @default.
• W3111444324 hasConcept C159654299 @default.
• W3111444324 hasConcept C17991360 @default.
• W3111444324 hasConcept C203014093 @default.
• W3111444324 hasConcept C2777138892 @default.
• W3111444324 hasConcept C2777226972 @default.
• W3111444324 hasConcept C2777575956 @default.
• W3111444324 hasConcept C2778715236 @default.
• W3111444324 hasConcept C2779384505 @default.
• W3111444324 hasConcept C2780132546 @default.
• W3111444324 hasConcept C32611913 @default.
• W3111444324 hasConcept C71924100 @default.
• W3111444324 hasConcept C90924648 @default.
• W3111444324 hasConceptScore W3111444324C126322002 @default.
• W3111444324 hasConceptScore W3111444324C159654299 @default.
• W3111444324 hasConceptScore W3111444324C17991360 @default.
• W3111444324 hasConceptScore W3111444324C203014093 @default.
• W3111444324 hasConceptScore W3111444324C2777138892 @default.
• W3111444324 hasConceptScore W3111444324C2777226972 @default.
• W3111444324 hasConceptScore W3111444324C2777575956 @default.
• W3111444324 hasConceptScore W3111444324C2778715236 @default.
• W3111444324 hasConceptScore W3111444324C2779384505 @default.
• W3111444324 hasConceptScore W3111444324C2780132546 @default.
• W3111444324 hasConceptScore W3111444324C32611913 @default.
• W3111444324 hasConceptScore W3111444324C71924100 @default.
• W3111444324 hasConceptScore W3111444324C90924648 @default.
• W3111444324 hasIssue "12" @default.
• W3111444324 hasLocation W31114443241 @default.
• W3111444324 hasLocation W31114443242 @default.
• W3111444324 hasLocation W31114443243 @default.
• W3111444324 hasOpenAccess W3111444324 @default.
• W3111444324 hasPrimaryLocation W31114443241 @default.
• W3111444324 hasRelatedWork W1555548379 @default.
• W3111444324 hasRelatedWork W1973470095 @default.
• W3111444324 hasRelatedWork W2015993259 @default.
• W3111444324 hasRelatedWork W2030855147 @default.
• W3111444324 hasRelatedWork W2100569870 @default.
• W3111444324 hasRelatedWork W2119801100 @default.
• W3111444324 hasRelatedWork W2167894048 @default.
• W3111444324 hasRelatedWork W23797247 @default.
• W3111444324 hasRelatedWork W2755566013 @default.
• W3111444324 hasRelatedWork W4200063390 @default.
• W3111444324 hasVolume "15" @default.
• W3111444324 isParatext "false" @default.
• W3111444324 isRetracted "false" @default.
• W3111444324 magId "3111444324" @default.
• W3111444324 workType "article" @default.